Trials / Completed
CompletedNCT01953783
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IXAZOMIB | Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21. Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity. |
Timeline
- Start date
- 2014-03-19
- Primary completion
- 2014-12-17
- Completion
- 2016-02-09
- First posted
- 2013-10-01
- Last updated
- 2020-08-26
- Results posted
- 2020-08-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01953783. Inclusion in this directory is not an endorsement.